Miravant gets conditional approval for AMD therapy
This article was originally published in Clinica
Executive Summary
The US FDA has granted Miravant Medical Technologies an "approvable letter" for its photodynamic therapy (PDT) for macular degeneration, but on the condition that the firm conducts an additional confirmatory clinical trial.